Sarepta to host conference call Management discusses plans to submit to the FDA, a New Drug Application by year end 2014, for Eteplirsen for treatment of Duchenne Muscular Dystrophy on a conference call to be held on April 21 at 8 am. Webcast Link
Sarepta upgraded to Outperform from Neutral at Baird As previously reported, Baird upgraded Sarepta to Outperform from Neutral and increased its price target to $20 from $16. The firm said last night's NDA submission by potential competitor BioMarin (BMRN) indicates the FDA will review both applications and expects Sarepta to solidify a mid-2015 submission following a Q2 meeting with the agency. Baird believes shares could trade above $20 once the NDA is accepted, versus downside of $6-$7 on a significant delay.
Rick Barry accepts nomination to join Sarepta board Rick Barry disclosed a 7.66% stake in Sarepta Therapeutics and noted he has been nominated to join the board of the company and has accepted the nomination. No additional purchase or disposition of securities occurred since the last filing of Schedule 13G on February 19, the current filing noted.